Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Eribulin Mesylate

FDA-approved product (solution, intravenous), marketed as Eribulin Mesylate, Halaven.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Eribulin Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Liposarcoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Eribulin Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Eribulin Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)

    NCT02513472 · start 2015-08-28

    Registered record
    Registry ID
    NCT02513472
    Conditions
    Breast Neoplasm
    Interventions
    Eribulin Mesylate; Pembrolizumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-08-28
    Completion
    2021-04-06
    Enrolment
    258

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasm
    InterventionEribulin Mesylate; Pembrolizumab
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

    NCT02492711 · start 2015-08-24

    Registered record
    Registry ID
    NCT02492711
    Conditions
    HER-2 Positive Breast Cancer; Metastatic Neoplasm
    Interventions
    Margetuximab; Trastuzumab; Physician's choice of chemotherapy.
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-08-24
    Completion
    2022-06-14
    Enrolment
    624

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER-2 Positive Breast Cancer; Metastatic Neoplasm
    InterventionMargetuximab; Trastuzumab; Physician's choice of chemotherapy.
    PhasePhase 3
    Registry statusCompleted

  • Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

    NCT02404506 · start 2015-08-17

    Registered record
    Registry ID
    NCT02404506
    Conditions
    Breast Cancer; Adenocarcinoma
    Interventions
    Eribulin mesilate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2015-08-17
    Completion
    2021-07-22
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Adenocarcinoma
    InterventionEribulin mesilate
    PhasePhase 2
    Registry statusTerminated

  • Retroprospective Real Life Observatory of Eribulin

    NCT02393287 · start 2014-11

    Registered record
    Registry ID
    NCT02393287
    Conditions
    Metastatic Breast Cancer
    Interventions
    Eribulin (ReProLine)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-11
    Completion
    2017-01
    Enrolment
    753

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionEribulin (ReProLine)
    PhaseNot recorded
    Registry statusCompleted

  • SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

    NCT02299999 · start 2014-04-07

    Registered record
    Registry ID
    NCT02299999
    Conditions
    Metastatic Breast Cancer
    Interventions
    AZD2014; AZD4547; AZD5363; AZD8931; Selumetinib; Vandetanib; Bicalutamide; Olaparib; Anthracyclines; Taxanes; cyclophosphamide; DNA intercalators; Methotrexate; vinca alkaloids; Platinum based chemotherapies; Bevacizumab; Mitomycin C; Eribulin; MEDI4736
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2014-04-07
    Completion
    2025-12
    Enrolment
    1,460

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionAZD2014; AZD4547; AZD5363; AZD8931 +15 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

    NCT02037529 · start 2014-01-17

    Registered record
    Registry ID
    NCT02037529
    Conditions
    Breast Adenocarcinoma; HER2/Neu Negative; Invasive Breast Carcinoma; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7
    Interventions
    Eribulin Mesylate; Laboratory Biomarker Analysis; Paclitaxel; Quality-of-Life Assessment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Suspended
    Start
    2014-01-17
    Completion
    2024-10-31
    Enrolment
    201

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Adenocarcinoma; HER2/Neu Negative; Invasive Breast Carcinoma; Stage IIIC Breast Cancer AJCC v7 +1 more
    InterventionEribulin Mesylate; Laboratory Biomarker Analysis; Paclitaxel; Quality-of-Life Assessment
    PhasePhase 3
    Registry statusSuspended

  • First Line Metastatic Breast Cancer Treatment (ESMERALDA)

    NCT01941407 · start 2013-11

    Registered record
    Registry ID
    NCT01941407
    Conditions
    Metastatic Breast Cancer
    Interventions
    Eribulin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-11
    Completion
    2016-03
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionEribulin
    PhasePhase 2
    Registry statusCompleted

  • Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

    NCT02225470 · start 2013-09-26

    Registered record
    Registry ID
    NCT02225470
    Conditions
    HER2-Negative Breast Cancer; Triple Negative Breast Cancer; Breast Cancer; Cancer of Breast; Breast Tumors
    Interventions
    E7389 (Eribulin Mesylate); Vinorelbine injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-09-26
    Completion
    2018-06-22
    Enrolment
    530

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-Negative Breast Cancer; Triple Negative Breast Cancer; Breast Cancer; Cancer of Breast +1 more
    InterventionE7389 (Eribulin Mesylate); Vinorelbine injection
    PhasePhase 3
    Registry statusCompleted

  • Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer

    NCT01837095 · start 2013-06

    Registered record
    Registry ID
    NCT01837095
    Conditions
    Metastatic Breast Cancer
    Interventions
    POL6326
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-06
    Completion
    2018-08
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionPOL6326
    PhasePhase 1
    Registry statusCompleted

  • Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer

    NCT01961544 · start 2013-06

    Registered record
    Registry ID
    NCT01961544
    Conditions
    Breast Neoplasms; Breast Cancer
    Interventions
    Eribulin mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-06
    Completion
    2015-07
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms; Breast Cancer
    InterventionEribulin mesylate
    PhasePhase 4
    Registry statusCompleted

  • A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients

    NCT01795586 · start 2013-02-06

    Registered record
    Registry ID
    NCT01795586
    Conditions
    Breast Cancer
    Interventions
    Eribulin; Carboplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-02-06
    Completion
    2022-05-11
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionEribulin; Carboplatin
    PhasePhase 1
    Registry statusCompleted

  • Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

    NCT01593020 · start 2012-08-03

    Registered record
    Registry ID
    NCT01593020
    Conditions
    Breast Cancer
    Interventions
    Paclitaxel; Eribulin; 5-Fluorouracil; Epirubicin; Cyclophosphamide; Doxorubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-08-03
    Completion
    2020-11-04
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionPaclitaxel; Eribulin; 5-Fluorouracil; Epirubicin +2 more
    PhasePhase 2
    Registry statusCompleted

  • Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer

    NCT02790320 · start 2012-06

    Registered record
    Registry ID
    NCT02790320
    Conditions
    Metastatic Breast Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-06
    Completion
    2012-11
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)

    NCT01534455 · start 2012-02

    Registered record
    Registry ID
    NCT01534455
    Conditions
    Metastatic Breast Cancer
    Interventions
    Lapatinib + 1,23 mg Eribulin; Lapatinib + 1,76 mg Eribulin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2012-02
    Completion
    2015-03
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionLapatinib + 1,23 mg Eribulin; Lapatinib + 1,76 mg Eribulin
    PhasePhase 2
    Registry statusTerminated

  • Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

    NCT01498588 · start 2011-11

    Registered record
    Registry ID
    NCT01498588
    Conditions
    Breast Neoplasms; Breast Cancer; Breast Tumors; Cancer of the Breast; Neoplasms, Breast; Tumors, Breast
    Interventions
    Eribulin; Doxorubicin; Cyclophosphamide; Pegfilgrastim
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-11
    Completion
    2015-06
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms; Breast Cancer; Breast Tumors; Cancer of the Breast +2 more
    InterventionEribulin; Doxorubicin; Cyclophosphamide; Pegfilgrastim
    PhasePhase 2
    Registry statusTerminated